Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: The Dallas Heart Study

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 833-838

  Chen, Lu Q ^a   Rohatgi, Anand ^a,b   Ayers, Colby R ^b   Das, Sandeep R ^a,b   Khera, Amit ^a,b   Berry, Jarett D ^a,b   McGuire, Darren K ^a,b   de Lemos, James A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

African American; Atherosclerosis; Myeloperoxidase; Peripheral vascular disease

Indexed keywords

MYELOPEROXIDASE;

ABDOMINAL AORTA PLAQUE BURDEN; ABDOMINAL AORTA PLAQUE PREVALENCE; ABDOMINAL AORTA WALL THICKNESS; ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR PARAMETERS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; DISEASE ASSOCIATION; ELECTRON BEAM TOMOGRAPHY; EUROPEAN AMERICAN; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; THICKNESS;

ADULT; AFRICAN AMERICANS; AORTA, ABDOMINAL; AORTIC DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; ODDS RATIO; PEROXIDASE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TEXAS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 82955211373     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.029     Document Type: Article

References (32)

1. Daugherty A., Dunn J.L., Rateri D.L., Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
2. Zhang R., Brennan M.L., Shen Z., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002, 277:46116-46122.
3. Yang J., Cheng Y., Ji R., Zhang C. Novel model of inflammatory neointima formation reveals a potential role of myeloperoxidase in neointimal hyperplasia. Am J Physiol Heart Circ Physiol 2006, 291:H3087-H3093.
4. Ronald J.A., Chen J.W., Chen Y., et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009, 120:592-599.
5. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158:879-891.
6. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99:2075-2081.
7. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
8. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
9. Ndrepepa G., Braun S., Mehilli J., von Beckerath N., Schomig A., Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008, 38:90-96.
10. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
11. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national health and nutrition examination survey, 1999-2000. Circulation 2004, 110:738-743.
12. Zirlik A., Abdullah S.M., Gerdes N., et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:2043-2049.
13. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
14. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in c-reactive protein levels. J Am Coll Cardiol 2005, 46:464-469.
15. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 2004, 93:1473-1480.
16. Jain T., Peshock R., McGuire D.K., et al. African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol 2004, 44:1011-1017.
17. Rohatgi A., Ayers C.R., Khera A., et al. The association between peptidoglycan recognition protein-1 and coronary and peripheral atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 2009, 203:569-575.
18. Jaffer F.A., O'Donnell C.J., Larson M.G., et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002, 22:849-854.
19. Rosero E.B., Peshock R.M., Khera A., Clagett P., Lo H., Timaran C.H. Sex, race, and age distributions of mean aortic wall thickness in a multiethnic population-based sample. J Vasc Surg 2011, 53:950-957.
20. Rosero E.B., Peshock R.M., Khera A., Clagett G.P., Lo H., Timaran C. Agreement between methods of measurement of mean aortic wall thickness by MRI. J Magn Reson Imaging 2009, 29:576-582.
21. Nguyen A.B., Rohatgi A., Garcia C.K., et al. Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2011, 31:2136-2143.
22. Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44:1812-1818.
23. Lindsey J.B., de Lemos J.A., Cipollone F., et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009, 32:1218-1220.
24. Abu-Soud H.M., Hazen S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000, 275:37524-37532.
25. Apple F.S., Smith S.W., Pearce L.A., Murakami M.M. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009, 55:93-100.
26. Ali Z., Sarcia P., Mosley T.H., Kondragunta V., Kullo I.J. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med 2009, 14:215-220.
27. Exner M., Minar E., Mlekusch W., et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006, 47:2212-2218.
28. Meuwese M.C., Trip M.D., van Wissen S., van Miert J.N., Kastelein J.J., Stroes E.S. Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 2008, 197:916-921.
29. Wong N.D., Gransar H., Narula J., et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009, 2:1093-1099.
30. Grodin J.L., Powell T.M., Rohatgi A., Khera A., et al. Matrix metalloproteinase-9 is independently associated with aortic wall thickness: from the Dallas Heart Study. Circulation 2010, A18342. [abstract].
31. Kullo I.J., Bailey K.R., Kardia S.L., Mosley T.H., Boerwinkle E., Turner S.T. Ethnic differences in peripheral arterial disease in the nhlbi genetic epidemiology network of arteriopathy (genoa) study. Vasc Med 2003, 8:237-242.
32. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.